{"id":57630,"date":"2025-06-09T16:57:24","date_gmt":"2025-06-09T20:57:24","guid":{"rendered":"https:\/\/www.rudebaguette.com\/?p=57630"},"modified":"2025-06-08T17:17:13","modified_gmt":"2025-06-08T21:17:13","slug":"neuralink-could-shut-down-over-this-rival-company-implants-brain-chip-in-human-first-and-destroys-musks-lead","status":"publish","type":"post","link":"https:\/\/www.rudebaguette.com\/en\/2025\/06\/neuralink-could-shut-down-over-this-rival-company-implants-brain-chip-in-human-first-and-destroys-musks-lead\/","title":{"rendered":"\u201cNeuralink Could Shut Down Over This\u201d: Rival Company Implants Brain Chip in Human First and Destroys Musk\u2019s Lead"},"content":{"rendered":"
\n\n\n\n\n
IN A NUTSHELL<\/strong><\/td>\n<\/tr>\n
\n
    \n
  • \ud83d\ude80 Paradromics<\/strong> achieved a major milestone by successfully implanting its Connexus BCI<\/strong> device in a human during a scheduled epilepsy surgery.<\/li>\n
  • \ud83d\udd2c The procedure marks Paradromics’ transition to a clinical-stage company, setting the stage for upcoming clinical trials<\/strong> and potential FDA approval<\/strong>.<\/li>\n
  • \ud83c\udf0d With nearly $100 million in funding and a partnership with Saudi Arabia\u2019s NEOM<\/strong> project, Paradromics aims to expand its global influence in the neurotech<\/strong> industry.<\/li>\n
  • \ud83e\udde0 The success of this technology could revolutionize communication for individuals with severe motor impairments, highlighting the transformative potential of brain-computer interfaces<\/strong>.<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

    In the rapidly evolving world of neurotechnology, the race to develop effective brain-computer interfaces (BCIs) intensifies. Among the contenders is Paradromics, a Texas-based startup that recently made headlines by successfully implanting its BCI device in a human. This significant milestone not only places Paradromics in direct competition with prominent players like Elon Musk\u2019s Neuralink but also underscores the potential impact of BCIs on medical and technological advancements. As Paradromics gears up for clinical trials, the implications of this technology continue to captivate both the scientific community and the general public.<\/p>\n

    The Paradromics Breakthrough<\/h2>\n

    Paradromics<\/strong> has boldly entered the neurotech arena, making significant strides in the development of brain-computer interfaces. Founded in 2015, the company achieved a remarkable feat by successfully implanting and removing its Connexus BCI device during a scheduled epilepsy surgery at the University of Michigan. This 20-minute procedure marked a critical milestone for Paradromics, demonstrating the device’s capabilities in a human brain. By recording neural activity, the Connexus BCI showcases its potential to translate brain signals into actionable commands, paving the way for broader applications in medical treatments.<\/p>\n

    With this success, Paradromics aims to bring its technology from the laboratory to clinical settings. While the device has yet to receive approval from the U.S. Food and Drug Administration (FDA), the recent achievement signals a promising future. According to founder and CEO Matt Angle, this surgery has transitioned Paradromics into a clinical-stage company, highlighting the potential for BCIs to transform patient care. As the company moves forward, its focus on leveraging high-resolution data from individual neurons sets it apart from competitors, positioning Paradromics as a leader in the BCI landscape.<\/p>\n

    \u201cMind Controls YouTube\u201d: Neuralink Chip Lets Nonverbal Patient Publish First Video Using Only Thoughts and Brain Signals<\/a><\/p><\/blockquote>\n